Literature DB >> 8969245

New vaccines for the prevention of pneumococcal infections.

H Käyhty1, J Eskola.   

Abstract

Streptococcus pneumoniae is a major cause of acute otitis media, pneumonia, bacteremia, and meningitis. Because in recent years antibiotic-resistant pneumococcal strains have been emerging throughout the world, vaccination against pneumococcal infections has become more urgent. The capsular polysaccharide vaccine that has been available is neither immunogenic nor protective in young children and other immunocompromised patients. Several pneumococcal proteins have been proposed as candidate vaccines, but no human studies associated with them have been reported. Clinical trials of first-generation pneumococcal conjugate vaccines have shown that covalent coupling of pneumococcal capsular polysaccharides to protein carriers improves the immunogenicity of the polysaccharides. The protective efficacy of the conjugate vaccines against carriage, acute otitis media, and invasive infections is being studied.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8969245      PMCID: PMC2639933          DOI: 10.3201/eid0204.960404

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  47 in total

1.  Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children.

Authors:  I D Riley; D Lehmann; M P Alpers; T F Marshall; H Gratten; D Smith
Journal:  Lancet       Date:  1986-10-18       Impact factor: 79.321

2.  Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants.

Authors:  E L Anderson; D J Kennedy; K M Geldmacher; J Donnelly; P M Mendelman
Journal:  J Pediatr       Date:  1996-05       Impact factor: 4.406

3.  Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants.

Authors:  A Leach; S J Ceesay; W A Banya; B M Greenwood
Journal:  Pediatr Infect Dis J       Date:  1996-04       Impact factor: 2.129

4.  Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.

Authors:  J E Alexander; R A Lock; C C Peeters; J T Poolman; P W Andrew; T J Mitchell; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

5.  Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children.

Authors:  P A Shurin; J M Rehmus; C E Johnson; C D Marchant; S A Carlin; D M Super; G F Van Hare; P K Jones; D M Ambrosino; G R Siber
Journal:  J Pediatr       Date:  1993-11       Impact factor: 4.406

6.  Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.

Authors:  R Schneerson; J B Robbins; J C Parke; C Bell; J J Schlesselman; A Sutton; Z Wang; G Schiffman; A Karpas; J Shiloach
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

7.  Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution.

Authors:  J H van de Wijgert; A F Verheul; H Snippe; I J Check; R L Hunter
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

8.  Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model.

Authors:  G S Giebink; J D Meier; M K Quartey; C L Liebeler; C T Le
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

9.  Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats.

Authors:  M Kauppi; L Saarinen; H Käyhty
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

10.  Pneumococcal vaccine and otitis media.

Authors:  P H Mäkelä; M Sibakov; E Herva; J Henrichsen; J Luotonen; M Timonen; M Leinonen; M Koskela; J Pukander; S Pöntynen; P Grönroos; P Karma
Journal:  Lancet       Date:  1980-09-13       Impact factor: 79.321

View more
  19 in total

1.  Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F.

Authors:  A H Lucas; K D Moulton; V R Tang; D C Reason
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.

Authors:  R S Chu; T McCool; N S Greenspan; J R Schreiber; C V Harding
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

3.  Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides.

Authors:  W R Usinger; A H Lucas
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis.

Authors:  J E Adamou; J H Heinrichs; A L Erwin; W Walsh; T Gayle; M Dormitzer; R Dagan; Y A Brewah; P Barren; R Lathigra; S Langermann; S Koenig; S Johnson
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

5.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

Review 6.  Cancer vaccines and carbohydrate epitopes.

Authors:  Jamie Heimburg-Molinaro; Michelle Lum; Geraldine Vijay; Miten Jain; Adel Almogren; Kate Rittenhouse-Olson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

7.  Identification of the psaA gene, coding for pneumococcal surface adhesin A, in viridans group streptococci other than Streptococcus pneumoniae.

Authors:  I Jado; A Fenoll; J Casal; A Pérez
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 8.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

9.  Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996-2005.

Authors:  C A Ihekweazu; D A B Dance; R Pebody; R C George; M D Smith; P Waight; H Christensen; K A V Cartwright; J M Stuart
Journal:  Epidemiol Infect       Date:  2007-10-26       Impact factor: 2.451

10.  Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

Authors:  Jasper M Bos; Hans C Rümke; Robert Welte; Lodewijk Spanjaard; Loek van Alphen; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.